Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • VisualDx Now Available at Northeast Ohio Medical University

    Mar 19, 2021, 15:39 PM by
    Full story
  • CluePoints Sponsors RBQM Live

    Mar 19, 2021, 15:39 PM by
    Full story
  • THREAD and CureClick Partner to Accelerate Recruitment for Decentralized Clinical Trials

    Mar 19, 2021, 15:39 PM by
    Full story
  • Bally Ribbon Mills Bringing Smart Textiles to Commercialization

    Mar 19, 2021, 15:39 PM by
    Bally Ribbon Mills Bringing Smart Textiles to Commercialization Incorporating E-WEBBINGS® e-textile product base into new designs
    Full story
  • Accurics Launches Comprehensive Channel Program with Unique Developer-First Approach to Cloud Security

    Mar 19, 2021, 15:39 PM by
    Full story
  • ComputaBio Has Launched Virtual Screening Service to Assist Drug Design

    Mar 19, 2021, 15:39 PM by
    ComputaBio, a US based supplier of full-range computational biology services, has launched virtual screening service to assist drug design.
    Full story
  • Watson-Marlow Fluid Technology Group launches new website to support ongoing growth

    Mar 19, 2021, 15:39 PM by
    Watson-Marlow Fluid Technology Group (WMFTG) announces the launch of its upgraded website. The new website will reflect its sectorised sales strategy and future proof for upcoming global expansion plans to support more essential industries including biopharmaceutical, medical technology, water, food and waste.
    Full story
  • Lyniate Collaborates with Sensato and SES to Further Empower Provider and Public Health Organizations

    Mar 19, 2021, 15:39 PM by
    Lyniate, a global leader in healthcare data interoperability, today announced new partnerships with two healthcare technology innovators: clinical exchange technology provider Secure Exchange Solutions (SES) and healthcare cybersecurity firm Sensato.
    Full story
  • Certara Adopts TrialAssure ANONYMIZE Solution to Speed Life Science Industry Need to Meet Regulatory Requirements for Data Sharing

    Mar 19, 2021, 15:39 PM by
    TrialAssure® – a leading, global software company advancing clinical trial disclosure, data sharing, and transparency – has announced today that Certara (Nasdaq: CERT) – the global leader in biosimulation – has licensed TrialAssure’s ANONYMIZE software to anonymize clinical data.
    Full story
  • Future Planet Invests in Vaccitech’s Series B Financing

    Mar 19, 2021, 15:39 PM by
    Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd.
    Full story
  • Pronalyse: Antibody Analysis Service Is Released to Boost Drug Discovery

    Mar 19, 2021, 15:39 PM by
    Full story
  • CRISPR/Cas9 Gene Editing Service Now Available by the GutFlora Omics Platform

    Mar 19, 2021, 15:39 PM by
    Full story
  • Bioinformatics-Analysis Division Revised Website for Better User Experience

    Mar 19, 2021, 15:39 PM by
    Full story
  • THREAD Launches New Telehealth Features Expanding Video and Audio Capture for Complex eCOA during Virtual Visits in Decentralized Clinical Trials

    Mar 19, 2021, 15:39 PM by
    THREAD, a technology and service provider enabling decentralized clinical trials (DCTs), today announced the launch of new telehealth features. Building on four years of conducting electronic clinical outcome assessments (eCOA) during telehealth virtual visits, the new features raise the bar in DCT telehealth functionality by adding several unique enhancements to the company’s industry-leading eCOA and telehealth virtual visit solution. New features allow clinical study stakeholders – including sponsors, caregivers, home health professionals and raters – to remotely and safely capture video and/or audio recordings in real time.
    Full story
  • MicrobioSeq Releases Microecology and Cancer Solutions to Accelerate Your Cancer Research and Discovery

    Mar 19, 2021, 15:39 PM by
    Full story
  • Irish Company Develops Cloud-Based App Aimed to Accelerate Global COVID-19 Vaccination Process

    Mar 19, 2021, 15:39 PM by
    Full story
  • RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine

    Mar 19, 2021, 15:39 PM by
    Notes to editors Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. RDIF has established joint strategic partnerships with leading international co-investors from over 18 countries attracting over $40 bn of capital. Further information can be found at rdif.ru For more information about the Sputnik vaccine please visit sputnikvaccine.com/ Stelis Biopharma Pvt. Ltd. (Stelis) is a vertically integrated biopharmaceutical company. Stelis offers end-to-end state-of-the-art CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. Its operations include R&D, process development, scale-up & end-to-end cGMP manufacturing capabilities from drug substance through drug product in all formats and packaging. Stelis is also developing select follow-on biologic products for global markets in niche and commercially attractive disease categories. Stelis has recently forayed into Vaccine manufacturing with a capability to do multiple vaccine types. Stelis’ state-of-the-art research & development facility and 200,000 sq. ft. fully integrated cGMP manufacturing facility are located in Bengaluru, India. Facilities cater to the development and cGMP manufacturing of biologics and injectables conforming to international standards. For more information visit www.stelis.com Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com
    Full story
  • Samsung Biologics Unveils Strong Performance and Future Plans

    Mar 19, 2021, 15:39 PM by
    As the company celebrates its 10th anniversary this year, it is pleased to announce a strong 2020, reporting 1 Trillion won in sales!
    Full story
  • Jay Flatley Steps Down From Illumina Board

    Mar 18, 2021, 17:12 PM by User Not Found
    Bio-IT World | Illumina has announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair of the Board. These changes will be effective as of the Company’s Annual Shareholder Meeting on May 26, 2021.
    Full story
  • It’s Time to Bet on the Underdog

    Mar 18, 2021, 01:00 AM by User Not Found
    Bio-IT World | The unprecedented accomplishment that is Moderna’s innovative mRNA Covid-19 vaccine proves—among other things—that a shift has come to life sciences. It’s time to bet on the underdog.
    Full story
  • «
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176 (current)
  • 177
  • 178
  • 179
  • 180
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy